Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
Author: ["Bart L Haagmans","Thijs Kuiken","Byron E Martina","Ron A M Fouchier","Guus F Rimmelzwaan","Geert van Amerongen","Debby van Riel","Ton de Jong","Shigeyuki Itamura","Kwok-Hung Chan","Masato Tashiro","Albert D M E Osterhaus"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
The primary cause of severe acute respiratory syndrome (SARS) is a newly discovered coronavirus1,2,3,4,5,6,7. Replication of this SARS coronavirus (SCV) occurs mainly in the lower respiratory tract, and causes diffuse alveolar damage2,7,8. Lack of understanding of the pathogenesis of SARS has prevented the rational development of a therapy against this disease. Here we show extensive SCV antigen expression in type 1 pneumocytes of experimentally infected cynomolgus macaques (Macaca fascicularis) at 4 d postinfection (d.p.i.), indicating that this cell type is the primary target for SCV infection early in the disease, and explaining the subsequent pulmonary damage. We also show that prophylactic treatment of SCV-infected macaques with the antiviral agent pegylated interferon-α (IFN-α) significantly reduces viral replication and excretion, viral antigen expression by type 1 pneumocytes and pulmonary damage, compared with untreated macaques. Postexposure treatment with pegylated IFN-α yielded intermediate results. We therefore suggest that pegylated IFN-α protects type 1 pneumocytes from SCV infection, and should be considered a candidate drug for SARS therapy
Cite this article
Haagmans, B., Kuiken, T., Martina, B. et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 10, 290–293 (2004). https://doi.org/10.1038/nm1001
